VistaGen Therapeutics(US:VTGN) Prnewswire·2026-02-11 14:20Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1]. Group 1: Legal Action and Allegations - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and reminds investors of the March 16, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The complaint alleges that Vistagen and its executives violated federal securities laws by making false assertions about the likelihood of success for fasedienol based on prior clinical trial results [1]. - The lawsuit claims that these misleading statements caused investors to purchase Vistagen's stock at artificially inflated prices [1]. Group 2: Clinical Trial Results - On December 17, 2025, Vistagen announced that its PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint, showing no statistically significant improvement in anxiety reduction compared to placebo [1]. - Following the announcement of the failed trial results, Vistagen's stock price plummeted over 81%, opening at $0.88 per share [1].